Sellas Life Sciences Group Inc (NASDAQ:SLS)
| 1.70 BATS BZX Real-Time Price As of 10:51am ET |  -0.02 / -1.16%Today’s Change | 1.17 Today|||52-Week Range 5.58 | -27.97% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Year Trend | |||||
|---|---|---|---|---|---|---|
2015 | 2016 | 2017 | 2018 | |||
| Assets | Cash | 30.1M | 36.1M | 12.8M | 5.5M | |
| Short Term Investment Cash | 6.3M | -11.6M | -3.6M | -7.3M | ||
| Cash & Short Term Investments | 30.1M | 36.1M | 12.8M | 5.5M | ||
| Receivables | Receivables | 21.7M | 0.00 | 0.00 | 0.00 | |
| Inventories | Inventories | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Current Assets | Other Current Assets | 1.8M | 1.4M | 337.0K | 387.0K | |
| Current Assets | 53.6M | 37.5M | 13.1M | 5.8M | ||
| Total Assets | Intangible Assets | 28.0M | 28.0M | 19.5M | 10.4M | |
| Other Assets | 28.2M | 28.1M | 20.4M | 11.1M | ||
| Total Assets | 82.1M | 65.8M | 33.5M | 18.3M | ||
| Liabilities | Accounts Payable | 0.00 | 0.00 | 11.7M | 3.8M | |
| Short Term Debt | 4.7M | 16.4M | 8.4M | 0.00 | ||
| Accrued Expenses | 435.0K | 3.3M | 2.0M | 1.5M | ||
| Other Current Liabilities | 50.8M | 13.0M | 3.9M | 1.5M | ||
| Other Liabilities | 57.1M | 30.4M | 24.6M | 6.0M | ||
| Total Liabilities | Long Term Debt | 0.00 | 0.00 | 2.6M | 0.00 | |
| Deferred Taxes | -5.4M | -5.7M | -1.7M | -357.0K | ||
| Other Liabilities | 6.1M | 1.1M | 2.6M | 5.3M | ||
| Total Liabilities | 68.6M | 37.2M | 31.5M | 13.1M | ||
| Equity | Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Preferred Stock | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Common Equity | 13.5M | 28.7M | 2.1M | 5.2M | ||
| Total Shareholder Equity | 13.5M | 28.7M | 2.1M | 5.2M | ||
| Share Information | Common Shares Outstanding | 269.8K | 506.3K | 192.2K | 22.0M | |
| Addtl. Info. | No data currently available for this section. | |||||
